ClinicalImpactRET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Download All
In this comprehensive online program for pathologists and medical oncologists, gain expert guidance on optimal biomarker testing to identify patients with RET-dependent NSCLC and thyroid cancers and on integration of RET inhibitors into clinical practice. Read expert-authored commentaries, listen to a podcast, or watch an on-demand Webcast archived from a CCO live Webinar followed by downloading the associated slideset.
Marcia Brose, MD, PhD
Taofeek K. Owonikoko, MD, PhD
Karen L. Reckamp, MD, MS
Laura J. Tafe, MD

On-Demand Webcasts

In this engaging on-demand webcast of a live CCO webinar, learn how experts interpret the latest data on RET inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with RET-altered NSCLC or thyroid cancer.

Marcia Brose, MD, PhD Karen L. Reckamp, MD, MS Laura J. Tafe, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.25 Lifelong Learning point(s) Released: April 8, 2021 Expired: No longer available for credit

Watch this on-demand Webcast capturing a live CCO Webinar to learn more about the latest data on RET inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with RET-altered NSCLC or thyroid cancer.

Taofeek K. Owonikoko, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s) ABPath MOC: maximum of 0.75 Lifelong Learning point(s) Released: February 12, 2021 Expired: No longer available for credit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings